Bosutinib has a new indication in leukemia as a well as a newly-approved formulation.
This article was originally published by Targeted Oncology®.
The FDA has granted approval to bosutinib for the treatment of pediatric patients aged 1 year or older with CP-CML that is newly diagnosed or relapsed or refractory to prior therapy.1
Results from the phase 1/2 BCHILD study (NCT04258943) support the FDA’s decision to grant approval of bosutinib for this indication. The study showed that bosutinib had preliminary efficacy in patients with CP-CML compared with other second-generation tyrosine kinase inhibitors. The agent was also well-tolerated in patients.1,2
In the newly diagnosed CP-CML population, the median duration of follow-up was 4.2 months (range, 1.1-26.3 months). Bosutinib achieved a major cytogenetic response rate (MCyR) of 76.2% (95% CI, 52.8-91.8) and complete cytogenetic response rate (CCyR) of 71.4% (95% CI, 47.8-88.7). Further, the major molecular response rate was 28.6% (95% CI, 11.3-52.3).
Among patients with relapsed/refractory CP-CML, the median duration of follow-up was 23.2 months (range, 1-61.5 months). MCyR observed with bosutinib was 82.1% (95% CI, 63.1- 93.9), and the CCyR was 78.6% (95% CI, 59-91.7). Fourteen patients from the cohort achieved a MMR, and of them 2 patients lost MMR after 13.6 and 24.7 months on treatment, respectively.
Occurring in at least 20% of patients in the study, the most common adverse events were diarrhea, abdominal pain, vomiting, nausea, rash, fatigue, hepatic dysfunction, headache, pyrexia, decreased appetite, and constipation. Further, increased creatinine, increased alanine aminotransferase or aspartate aminotransferase, decreased white blood cell count, and decreased platelet count were the most common laboratory abnormalities, which were observed in 45% of patients or more.
References
1. FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia. News release. FDA. September 27, 2023. Accessed. September 27, 2023. https://tinyurl.com/bdza5my2
2. Pennesi E, Brivio E, Willemse ME, et al. Preliminary results from the first-in-child phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML). J Clin Oncol. 2023;41(suppl 16): 10017. doi:10.1200/JCO.2023.41.16_suppl.10017
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More